Today: 3 June 2026
Browse Category

Pharmaceuticals 22 November 2025 - 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk shares rebounded sharply on 26 November, with U.S. ADRs up 3.7% to $48.79 and Copenhagen shares closing 4.7% higher at DKK 314.20. The rally followed an FDA filing for a higher-dose Wegovy, Medicare pricing clarity, and renewed interest in the company’s next-generation obesity drug. Despite the gains, Copenhagen shares remain down nearly 50% year-to-date.
26 November 2025
···
Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer shares traded near $25.70 late Wednesday morning, down about 0.1%–0.2%. Zacks Research raised its 2025 earnings estimate for Pfizer to $3.15 per share, above Wall Street consensus. Thornburg Investment Management increased its Pfizer stake by 5.7% in Q2, now holding about 10.46 million shares. Pfizer’s next dividend payment is set for December 1.
26 November 2025
·
Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck shares closed Wednesday at $105.3, just below their 52-week high of $105.84, after a 0.3% dip. The stock has surged about 40% since late May, fueled by FDA approval of Keytruda and Padcev for bladder cancer and strong Q3 earnings. Trading volume reached nearly 3.9 million shares. Merck’s market cap stands above $260 billion.
26 November 2025
··
Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer closed Tuesday at $25.72, up nearly 2%, with a dividend yield of about 6.7% and a market cap near $146 billion. Unusual options activity clustered at the $25 strike followed new FDA approval for PADCEV plus Keytruda in bladder cancer and the completed Metsera obesity drug acquisition. Analyst target averages $28.56. Pfizer trades at a forward P/E of about 8.6, with 2025 total return up 3–4% year-to-date.
26 November 2025
··
Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck shares rose nearly 4% to $104–$105 in early afternoon trading Tuesday, nearing a 52-week high, after the FDA approved Keytruda plus Padcev for certain bladder cancer patients. The rally, boosted by a Wells Fargo upgrade and strong broker commentary, helped drive the Dow more than 400 points higher. Over 11 million Merck shares changed hands by midday.
25 November 2025
··
NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

Novo Nordisk ADRs rose 4.7% to $47.08 in late trading Tuesday after mid-stage trial data showed its experimental obesity drug amycretin led to up to 14.5% weight loss in type 2 diabetes patients. The rebound follows a 5% drop Monday on failed Alzheimer’s trials. NVO remains down over 50% in the past year and trades near 52-week lows amid guidance cuts and competition from Eli Lilly.
25 November 2025
··
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly shares closed at $1,092.4 on Tuesday, up over 2%, after Bernstein raised its price target to $1,300 citing optimism for the obesity drug orforglipron. The stock’s market value stands near $1 trillion, with shares up more than 50% in three months and trading above the average analyst target. Trading volume was about 1.2 million shares.
25 November 2025
··
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics closed at $34.65 on November 24, valuing the company at about $3.9 billion. The firm completed enrollment in its Phase 3 obesity trial VANQUISH-1 ahead of schedule, with its lead drug VK2735 now in late-stage testing. Shares remain volatile, trading far below their 52-week high of $56.25 but well above the low of $18.92. Viking has no approved products or product revenue.
25 November 2025
··
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck shares climbed nearly 4% to around $101.40 by early afternoon Monday, nearing 2025 highs after Wells Fargo upgraded the stock to “Overweight” and raised its price target to $125. The move followed new FDA approvals and pipeline updates. Options activity surged, with call volume outpacing puts more than 3:1. Merck’s market cap stood at about $252 billion.
24 November 2025
··
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Bristol Myers Squibb shares rose 4.3% to $48.24 Monday after renewed investor interest in Factor XIa blood-thinner drugs and its candidate milvexian. The company announced a hematology-focused virtual investor event for December 11. Despite the gain, BMY remains down about 14% for the year, trailing the S&P 500’s 13.6% rise. Q3 earnings beat expectations, with revenue up 3% to $12.2 billion.
24 November 2025
·
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly became the first pharmaceutical company to reach a $1 trillion market capitalization, with shares trading near $1,058 on Monday. The surge follows strong demand for its weight-loss and diabetes drugs Mounjaro and Zepbound, both based on tirzepatide. Lilly’s stock has climbed over 35% in 2025 and more than 75% since Zepbound’s late 2023 launch. The company now trades at about 50 times expected earnings.
24 November 2025
···
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk shares plunged about 9% in Copenhagen to their lowest since July 2021 after phase 3 Alzheimer’s trials for semaglutide failed to meet the primary endpoint. The NVO ADR dropped to around $43.1 in U.S. pre-market trading, down nearly 10%. Year-to-date, the stock is off more than 50%. The company will present top-line trial data on December 3.
24 November 2025
··
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) closed Friday at $4.17, up 8.31%, with volume near 33 million shares and trading near its 52-week low. MarketBeat reports a consensus “Hold” rating, with a $7.25 average price target and Q3 revenue down 80% year-on-year. Kingsview Wealth Management increased its RXRX stake by over 500% in Q2. About 89% of shares are institutionally held.
24 November 2025
···
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals’ first commercial fibromyalgia drug, Tonmya, is now available in U.S. pharmacies following FDA approval in August. TNXP shares closed Friday at $16.10, up 2.94%, but remain down about 51% for 2025. Market cap stands near $141 million, with negative net margins and a price-to-sales ratio of 13.7. Expanded share repurchase and ATM equity programs are in place.
23 November 2025
··
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer closed Friday at $25.04 per share, with a market cap near $140 billion and a dividend yield close to 7%. The company finalized a multibillion-dollar obesity drug acquisition, won a major U.S. cancer approval, issued $6 billion in bonds, and settled a $41.5 million lawsuit in Texas. Shares remain over 60% below pandemic highs. New analysis highlights both upside and ongoing risks.
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer closed Friday at $25.04, up 2.6%, with trading volume above 72 million shares. The company completed a $6 billion bond offering late Friday, spanning maturities from 2027 to 2065. Pfizer’s stock is down about 12% over the past year, despite a recent FDA cancer-drug approval and a multi-billion-dollar obesity drug deal. Dividend yield stands near 6.9%.
23 November 2025
···
Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer shares rose 2.62% to close at $25.04 Friday after the FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer and positive data emerged for its mRNA flu vaccine. Volume reached 73 million shares. The stock outperformed Johnson & Johnson and Eli Lilly but remains about 10% below its 52-week high. Pfizer is still down for the year and trades well below pandemic-era peaks.
22 November 2025
··
1 … 32 33 34 35 36 … 41

Latest articles

Snap Lags Nasdaq, Turnaround Pressure Rises

Snap Lags Nasdaq, Turnaround Pressure Rises

3 June 2026
Snap Inc. shares slid 1.5% to $5.76 Tuesday—about 45% below last July’s high—even as the broader market rose, spotlighting investor doubts about Snap’s turnaround despite first-quarter revenue growth, narrowed losses, and major cost cuts; ad growth remains sluggish and the upcoming Specs update on June 16 is seen as a key test for future revenue momentum.
INFQ back on radar after UK quantum push; shares jump

INFQ back on radar after UK quantum push; shares jump

3 June 2026
Infleqtion shares surged 12.4% to $19.87 in late New York trading after announcing Gold Sponsorship of Quantum Fringe 2026 and new U.K. quantum partnerships, as investors bet on government contracts and expanded manufacturing, despite a $30.3 million quarterly net loss and warnings of ongoing operating losses if public-sector funding slows.
Corning shares move after AI news

Corning shares move after AI news

3 June 2026
Corning soared 13.4% to $200.40 on heavy volume after Nvidia’s CEO spotlighted the need for optical links in AI data centers, with Corning’s recent Nvidia and Meta deals making it a top play on AI infrastructure; first-quarter core sales jumped 18% and optical sales surged 36%, but investors face risks from consumer electronics demand and execution on new factory expansions.
Quantum computing stocks face a holiday week after IonQ stake filing and a Rigetti downgrade

IonQ Stock Jumped Again. A Giant Quantum IPO Is Putting the Trade on Trial

3 June 2026
IonQ shares closed up 3.1% at $71.40 before slipping 1.3% after hours as traders positioned ahead of Quantinuum’s upsized IPO, which seeks up to $1.46 billion at a $14.3 billion valuation; IonQ’s Q1 revenue surged 755% to $64.7 million with a raised 2026 outlook, but a $271.5 million operating loss and guidance for continued high expenses highlight risks as Wall Street awaits new sector benchmarks.
Xos Surges After Hours as Data-Center Power Play Hits Tape

Xos Surges After Hours as Data-Center Power Play Hits Tape

3 June 2026
Xos shares soared 135.8% to $5.26 in after-hours trading after launching a 2.5MWh Power Hub for data centers facing grid delays, but the company warned of "substantial doubt" about its ability to continue as a going concern, with just $9.8 million in cash at March 31 and no large orders yet announced for the new product.
Go toTop